Sep 26, 2019- Proclaim™ XR neurostimulation system uses Abbott's proprietary, low energy BurstDR™ therapy coupled with the BoldXR™ low dosing protocol for safe, effective pain relief and a battery that lasts up to 10 Years*- More than 50 million people in the United States are affected by chronic pain- Abbott's low-dose and low-energy pain management technology is designed to provide pain relief and improve system longevity, offering patients a life-altering option for pain relief without the hassles of recharging- Sep 25, 2019Newly cleared diagnostic test could help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women
- Sep 17, 2019- World's smallest pediatric treatments pioneered by Abbott address critical needs for the most vulnerable patients: babies and children born with common congenital heart defects- Includes pediatric mechanical heart valve and first minimally invasive device to treat premature babies and newborns born with an opening in their heart
- Sep 16, 2019- Abbott achieves top scores across all three key areas of economic, social and environmental performance, earns more than double the average score in Health Care Equipment & Supplies industry sector- Company's longstanding commitment to sustainability demonstrated by inclusion on DJSI for 15 consecutive years